Prostate-specific antigen. Current role in diagnostic pathology of prostate cancer
- PMID: 7524305
Prostate-specific antigen. Current role in diagnostic pathology of prostate cancer
Abstract
Prostate-specific antigen is the most important, accurate, and clinically useful biochemical marker in the prostate. It is manufactured by the secretory epithelial cells and drains into the ductal system, where it catalyzes the liquefaction of the seminal coagulum after ejaculation. Serum levels are normally less than 4 ng/mL (monoclonal) but vary according to patient age and race; any process that disrupts the normal architecture of the prostate allows diffusion of prostate-specific antigen into the stroma and microvasculature. Elevated serum prostate-specific antigen levels are seen with prostatitis, infarcts, hyperplasia, and transiently after biopsy, but the most clinically important increases are seen with prostatic adenocarcinoma. Cancer produces less prostate-specific antigen per cell than benign epithelium, but the greater number of malignant cells and the stromal disruption associated with cancer account for the increased serum prostate-specific antigen level. Serum prostate-specific antigen level correlates positively with clinical stage, tumor volume, histologic grade, and the presence of capsular perforation and seminal vesicle invasion; despite these strong correlations, its value is limited in predicting stage for individual patients. It may also predict the presence of lymph node metastases, bone metastases, and survival after androgen-deprivation therapy. The use of prostate-specific antigen has resulted in an increase in the early detection rate of cancer, and it is now advocated for annual routine use in men older than 40 years who are at increased risk and in all men older than 50 years. It is a test with high sensitivity and specificity that is rapid, inexpensive, minimally invasive, and acceptable to patients. In addition to serum prostate-specific antigen level, five derivatives of serum prostate-specific antigen were recently described that may increase the predictive value by accounting for confounding variables such as patient age, prostate volume, and cancer volume: age-specific reference ranges, prostate-specific antigen density, prostate-specific antigen velocity, prostate-specific antigen cancer density, and prostate-specific antigen doubling times. Serum prostate-specific antigen detects a heterogeneous group of cancers (clinical stage T1c) that are clinically important and potentially curable. Immunohistochemical expression of prostate-specific antigen in tissue sections allows determination of the prostatic origin of some metastatic adenocarcinomas, although extraprostatic expression of prostate-specific antigen has been reported in several tissues and tumors, including periurethral gland adenocarcinoma in women, rectal carcinoid, and extramammary Paget disease.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.J Urol. 1999 Apr;161(4):1233-7. J Urol. 1999. PMID: 10081876
-
The role of prostate-specific antigen in the chemoprevention of prostate cancer.J Cell Biochem Suppl. 1996;25:149-55. J Cell Biochem Suppl. 1996. PMID: 9027612 Review.
-
Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.J Urol. 2002 Jan;167(1):103-11. J Urol. 2002. PMID: 11743285
-
Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate.J Urol. 1998 Nov;160(5):1722-6. J Urol. 1998. PMID: 9783940
-
Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer.J Urol. 1997 Aug;158(2):326-37. J Urol. 1997. PMID: 9224297 Review.
Cited by
-
Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing.Med Sci (Basel). 2022 Feb 18;10(1):15. doi: 10.3390/medsci10010015. Med Sci (Basel). 2022. PMID: 35225948 Free PMC article. Review.
-
Study the Expression of CD10 in Prostate Carcinoma and its Correlation with Various Clinicopathological Parameters.Iran J Pathol. 2019 Spring;14(2):135-145. doi: 10.30699/IJP.14.2.135. Epub 2019 Jun 10. Iran J Pathol. 2019. PMID: 31528170 Free PMC article.
-
Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies.Nat Rev Urol. 2019 Jan;16(1):7-22. doi: 10.1038/s41585-018-0119-5. Nat Rev Urol. 2019. PMID: 30479377 Free PMC article. Review.
-
Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues.Biomed Res Int. 2013;2013:283635. doi: 10.1155/2013/283635. Epub 2013 Nov 25. Biomed Res Int. 2013. PMID: 24371818 Free PMC article. Review.
-
Bioinformatic identification of proteins with tissue-specific expression for biomarker discovery.BMC Med. 2012 Apr 19;10:39. doi: 10.1186/1741-7015-10-39. BMC Med. 2012. PMID: 22515324 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical